How to Help Your Patients Save Money on Padcev: A Provider's Guide to Savings Programs

Padcev (enfortumab vedotin-ejfv) is one of the most transformative treatment advances for urothelial cancer in a generation — but its cost puts significant financial strain on patients. A single 20 mg vial costs approximately $2,793, and many patients require multiple vials per dose, given twice per cycle. Annual treatment costs can easily exceed $200,000 without assistance.

As an oncology provider, your team plays a critical role in connecting patients with the financial assistance programs that exist. This guide consolidates every available savings pathway for Padcev in 2026, with actionable steps your team can implement.

Program 1: PADCEV Copay Assistance Program

The PADCEV Copay Assistance Program is the highest-impact savings tool for commercially insured patients:

Benefit: Reduces patient cost to as little as $5 per dose

Annual cap: $25,000 per calendar year

Eligibility: Commercial health insurance (private/employer-sponsored) only. Excludes Medicare, Medicaid, TRICARE, VA, DoD, and other government programs.

Enrollment: Via the online Prescriber Portal at astellaspharmasupportsolutions.com or by faxing the completed Patient Enrollment Form to 1-877-747-6843

Provider action: Enroll patients at the time of prescribing — do not wait for the first invoice to arrive

Program 2: PADCEV Patient Assistance Program (PAP)

For patients who are uninsured or whose insurance excludes Padcev, the PADCEV PAP provides the medication at no cost:

Benefit: Padcev provided at no cost to patients

Eligibility: Uninsured OR insured but with non-coverage; meets financial eligibility requirements; valid U.S. shipping address; FDA-approved indication

Enrollment: Provider submits PAP application via PADCEV Support Solutions. Padcev is shipped directly to the provider's office once approved.

Contact: 1-888-402-0627, Monday–Friday, 8:30 AM–8:00 PM ET

Program 3: Pfizer RxPathways and Oncology Together

Because Padcev is co-commercialized with Pfizer, patients may also access Pfizer's financial support programs:

Pfizer RxPathways: Connects patients to insurance support, co-pay help, and free medicine programs. Available at pfizerrxpathways.com.

Pfizer Oncology Together: A support program providing resources beyond financial assistance, including nurse education and patient support. Call 1-844-989-4766.

Strategies for Medicare and Medicaid Patients

Manufacturer copay programs exclude government insurance. For Medicare and Medicaid patients, pursue these pathways:

Ensure correct Part B billing: Padcev is billed under Medicare Part B (J9177) when administered at an infusion center. Verify the infusion site accepts Medicare Part B assignment — patients at non-assigned providers may face significantly higher costs.

Medigap supplemental insurance: Encourage eligible Medicare patients to enroll in Medigap (Medicare Supplement Insurance) coverage, which can cover the 20% Part B coinsurance, eliminating most out-of-pocket costs.

Independent nonprofit foundations: These organizations offer copay assistance for Medicare patients with qualifying diagnoses:

Patient Advocate Foundation (PAF) Co-Pay Relief Program: (800) 532-5274 | patientadvocate.org

HealthWell Foundation Bladder Cancer Fund: (800) 675-8416 | healthwellfoundation.org

Patient Access Network (PAN) Foundation: (866) 316-7263 | panfoundation.org

CancerCare Co-Payment Assistance Foundation: (866) 552-6729 | cancercare.org

39,483+ patients found their medications in stock

39K+

Find Padcev In Stock Today →

Billing Optimization to Reduce Patient Cost-Sharing

Billing choices can directly impact patient cost-sharing. Consider the following:

Site of service: Infusions administered in a hospital outpatient department (HOPD) typically have higher facility fees than independent or physician office-based infusion centers. For patients with significant cost-sharing, a non-HOPD site may dramatically reduce out-of-pocket costs.

Accurate J9177 billing: Verify that 1 billing unit = 0.25 mg. Overbilling leads to claim denials and patient liability; underbilling leads to reimbursement shortfalls that may be passed on to the patient.

Dose optimization: For patients weighing <100 kg, the dose may fall between vial sizes. Work with the infusion pharmacy to optimize vial use and avoid waste charges.

Building a Financial Navigation System in Your Practice

Best-in-class oncology practices have a structured financial navigation workflow. Implement these steps:

Assign a dedicated financial navigator or social worker to oncology patients being prescribed Padcev

Conduct benefits verification before the patient's first dose — not after

Enroll all eligible patients in the PADCEV Copay Assistance or PAP at prescription time

Maintain a contact list of foundation programs with current fund availability (fund availability changes — set a quarterly reminder to verify)

Screen patients for SSDI/Medicare eligibility if they have stopped working due to cancer

medfinder for providers can also help reduce administrative burden by locating available infusion sites for your patients — freeing your staff to focus on financial navigation and clinical support rather than facility searches.

See also: Padcev Access Challenges: What Providers and Prescribers Need to Know in 2026.